A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

This study is testing a drug called BIO 300 (a natural compound from soy) combined with standard radiation therapy for people who have early-stage non-small cell lung cancer (NSCLC) and also have interstitial lung disease (ILD) — a condition where the lungs become scarred and stiff. ILD makes radiation treatment riskier, and BIO 300 may help protect the lungs from radiation damage. **You may be eligible if...** - You are 18 or older - You have early-stage NSCLC (Stage I or II) - You have been diagnosed with interstitial lung disease (either by a lung specialist, imaging, or as a result of a connective tissue disease like lupus or rheumatoid arthritis) - You are in reasonably good health (ECOG performance status 0–3) - A pregnancy test is negative (if applicable) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have advanced-stage lung cancer - You do not have a confirmed ILD diagnosis Talk to your doctor to see if this trial is right for you.